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Abstract 
 
Tumour-associated microglia/macrophages (TAM) are the most numerous non-neoplastic 
populations in the tumour microenvironment in glioblastoma (GBM), the most common 
malignant brain tumour in adulthood. The mTOR pathway, an important regulator of cell 
survival/proliferation, is upregulated in GBM, but little is known about the potential role of this 
pathway in TAM. Here, we show that GBM-initiating cells (GIC) induce mTOR signalling in TAM-
Microglia (TAM-MG) but not TAM-Bone Marrow-derived Macrophages (TAM-BMDM) in both in 
vitro and in vivo GBM mouse models. mTOR-dependent regulation of STAT3 and NF-ĸB activity 
promotes an immunosuppressed phenotype in TAM-MG. This hinders effector T cell infiltration, 
proliferation, and immune reactivity, thereby contributing to tumour immune evasion and 
promoting tumour growth in a mouse model. The translational value of our results is 
demonstrated in whole transcriptome datasets of human GBM and in a novel in vitro model, 
whereby expanded-potential stem cells (EPSC)-derived microglia-like cells are conditioned by 
syngeneic patient-derived GIC. These results raise the possibility that TAM-MG could be the 
primary target of mTOR inhibition, rather than the intrinsic tumour cells in GBM.  
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Introduction 
 
No effective therapy currently exists for glioblastoma (GBM), which is the most common primary 
brain tumour and one of the most aggressive type of cancers. Challenges in tackling these 
tumours are manifold, including their inter- and intra-tumour heterogeneity, the limited 
accessibility of systemically administered drugs, their infiltrative growth pattern, and the 
complexity of the microenvironment in which they are embedded (Aldape et al, 2019).  
 
The contribution of the tumour microenvironment (TME), which is shaped by the communication 
between tumour cells and non-malignant cells, is undisputed in GBM pathogenesis (Quail & 
Joyce, 2017). Particular emphasis has been placed on immune infiltrates, including tumour-
associated microglia/macrophages (TAM), which are the most numerous infiltrating cell 
population in GBM (Chen et al, 2017; Darmanis et al, 2017; Roesch et al, 2018; Szulzewsky et 
al, 2015). These cells engage in a bidirectional interaction with tumour cells to promote several 
aspects of glioma development, including proliferation, angiogenesis, immune evasion, and 
therapeutic resistance (Chen & Hambardzumyan, 2018; Hambardzumyan et al, 2016). TAM in 
GBM are pro-tumourigenic, with increased accumulation in high grade gliomas that correlates 
with poor prognosis (Hambardzumyan et al., 2016; Komohara et al, 2008; Sorensen et al, 
2018). Moreover, TAM produce low levels of pro-inflammatory cytokines and lack key molecular 
mechanisms necessary for T cell stimulation, suggesting a suppression of T cell activation 
capacity in GBM (Hussain et al, 2007; Quail & Joyce, 2017). TAM can be classified into tumour-
associated microglia (TAM-MG), endogenous to central nervous system (CNS) tissue, and 
tumour-associated macrophages (TAM-BMDM), originating from bone marrow-derived 
monocytes that infiltrate the tumour from the periphery (Bowman et al, 2016; Haage et al, 2019; 
Muller et al, 2015). The functional contribution of TAM to GBM pathogenesis is well 
documented, however it is unclear how each of these two ontogenetically distinct populations 
differentially contribute to the GBM phenotype. 
 
Efforts are being invested in therapeutically depleting immune cells from the TME as well as 
altering cytotoxic potential with immunomodulation (Seoane, 2016). Targeting chemokines and 
their receptors such as the CCR2/CCL2 axes has been explored as a therapeutic strategy to 
inhibit infiltration of TAM (Ruffell & Coussens, 2015; Vakilian et al, 2017). For the re-education 
of TAM immune activity, inhibition of Colony stimulating factor 1 receptor (CSF1R) has shown 
promising result in preclinical GBM models by blocking tumour growth and progression 
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(Pyonteck et al, 2013; Yan et al, 2017). However, acquired resistance and tumour relapse 
emerge following long-term exposure to these therapies (Quail et al, 2016). To design 
successful re-education strategies targeting TAM, a better characterisation of their signalling 
mechanisms is essential.  
 
The mTOR pathway has been extensively studied in the context of cell growth, proliferation, and 
survival in many cancers, including GBM (Jhanwar-Uniyal et al, 2019; Li et al, 2016). The 
central component of the pathway, the mTOR protein kinase, forms the catalytic subunit of the 
protein complexes known as mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), 
which regulate different branches of the mTOR network (Shimobayashi & Hall, 2014; Yuan & 
Guan, 2016). mTORC1 signalling integrates inputs from inflammatory and growth factors as well 
as amino acids, energy status, oxygen levels and cellular stress pathways. The two major 
substrates of mTORC1 are p70 ribosomal protein S6 Kinase 1 (p70S6K1) and the eukaryotic 
translation initiation factor (eIF)-binding protein 1 (4EBP1) (LoRusso, 2016). These signalling 
molecules impact on cell growth and metabolism, in part by increasing the biosynthesis of the 
cellular translational apparatus (Thoreen et al, 2012). The small GTPase Ras homolog enriched 
in brain (Rheb) is the only known direct activator of mTORC1. Conversely, the signalling 
pathways that lead to mTORC2 activation are not characterised in such detail. mTORC2 is 
known to regulate cell cycle entry, cell survival and actin cytoskeleton polarisation through its 
most common downstream substrates: AKT, SGK and PKC (Yang et al, 2013). Despite their 
biochemical and functional differences, crosstalk has been reported between the two 
complexes, which contributes to the modulation of their activity (Xie & Proud, 2014). In GBM, 
altered mTORC1 signalling activity correlates with increased tumour grade and is associated 
with poor prognosis (Duzgun, Eroglu and Biray Avci, 2016). Consequently, mTOR kinase 
inhibitors targeting both mTORC1 and mTORC2 are considered promising anti-cancer therapies 
and are being tested in clinical trials, in combination with radiation and chemotherapy (Zhao et 
al., 2017; Mecca et al., 2018).  
 
In the last decade, extensive work has been carried out to characterise mTOR-dependent 
signalling in innate immune cells and its role in regulating the expression of inflammatory 
factors, antigen presentation, phagocytic activity, cell migration and proliferation (Weichhart et 
al., 2008; Jones and Pearce, 2017). mTOR signalling is known to regulate the balance between 
pro- and anti-inflammatory responses and may be responsible for the dysregulated 
inflammatory response in TAM, which display a shift towards anti-inflammatory activity. 
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Interestingly, increased mTOR phosphorylation at Ser-2448 is present in nearly 40% of TAM in 
human GBM (Lisi et al, 2019); however, the functional impact of this mTOR deregulation and its 
molecular mechanism have never been characterised. 
 
Here, we have used GBM orthotopic allografts in genetically engineered mice in which 
mTORC1 signalling has been silenced in TAM-MG, as well as human expanded-potential stem 
cells (EPSC)-derived microglial-like cells and matched GBM cells to study the role of the mTOR 
pathway in TAM-MG in the GBM microenvironment. 
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Results 
 
mTOR signalling is upregulated in TAM-MG but not TAM-BMDM in GBM mouse models. 
To determine whether mTOR signalling was deregulated in TAM, we assessed the activity of 
the pathway in GBM mouse models that recapitulate the genetic signatures of human GBM: 
GL261 allograft model, Ntv-a;PDGFB+Shp53 (Bowman et al., 2016), Pten-/-; p53-/- (Jacques et 
al, 2010), Pten-/-; p53-/-; Idh1R132H, and PDGFB genetic model (Zhang et al, 2019). Tumours were 
stained for Ionized calcium binding adaptor molecule 1 (Iba1, a marker of TAM) and for 
phosphorylated S6 (p-S6; S240/244, a downstream marker of mTORC1 activity). Co-expression 
of these markers, as defined by the fraction of Iba1+ cells expressing p-S6, was quantified. 
Three regions – non-tumour brain tissue, tumour edge, and tumour core – were defined and 
analysed separately, to account for potentially different functional properties of TAM within the 
tumour as compared to the surrounding brain, as previously reported (Darmanis et al., 2017) 
(Fig.1A). Tumour core regions were defined as highly cellular areas composed almost entirely of 
tumour cells (cells with marked pleomorphism and nuclear atypia - increased nuclear size and 
hyperchromasia - as well as mitotic activity on the Haematoxilin and Eosin (H&E) staining). The 
tumour edge refers to the infiltration zone whilst areas without tumour infiltration were defined as 
non-tumour brain tissue (Fig.1A). As expected, Iba1+ cells showed a ramified morphology with 
long, thin cellular processes and small cell bodies in non-tumour areas, whilst they displayed 
shorter and fewer processes, with rounder cell bodies at the tumour edge. In the tumour core, 
they acquired an amoeboid shape, without branched processes and large round cell bodies 
(Fig.1B). Quantification showed that p-S6+ Iba1+ cells were extremely low in the non-tumour 
tissue (ranging from 1% (±0.2 SEM) in the GL261 model to 13.9% (±7.4 SEM) in the PDGFB 
model), whereas co-expression was more frequent in the tumour core (between 50% and 83%, 
with the PDGFB model at 83% (±9.9 SEM) closely followed by the GL261 model at 71% (±8 
SEM)) (Fig.1B). In the tumour edge regions all models except Ntv-aPDGFB+Shp53 showed 
significant difference in the fraction of Iba1+ cells co-expressing p-S6 as compared to non-
tumour tissue (between 31% (±4 SEM) the GL261 model and 72% (±14 SEM) in the Pten-/-; p53-
/-model) (Fig.1B). We conclude that increased mTOR activity was consistently observed in TAM 
across tumour models and it was predominantly independent of intra-tumour location. 
Taking advantage of transcriptomic data from TAM-MG and TAM-BMDM isolated from GL261 
tumours (Bowman et al., 2016), deregulation of the mTOR pathway was further investigated in 
these two cell populations. 4907 and 5089 deregulated genes were identified in the comparison 
between healthy microglia and TAM-MG, and between blood monocytes and TAM-BMDM, 
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respectively. Amongst these deregulated genes, the majority were unique to TAM-MG and 
TAM-BMDM (3405 and 3687, respectively), in keeping with the different ontogeny of these cells 
(Fig.1C). The most significantly deregulated pathways identified by Ingenuity Pathway Analysis 
(IPA) (Kramer et al, 2014) in TAM-MG included mTOR signalling and mTOR-related signalling 
pathways: EIF2 signalling, regulation of eIF4 and p70S6K signalling, and mTOR signalling 
(Fig.1D). These pathways, as indicated by positive Z-score, were predicted to be activated 
(Fig.1D, Appendix Figure S1A and Dataset EV1). Importantly, these pathways were not 
detected as enriched when looking at the 5189 deregulated genes in TAM-BMDM (Fig.1E, 
Appendix Figure S1B), and upregulation of RPS6 and EI4EBP1 was detected in TAM-MG but 
not in TAM-BMDM compared to controls (Fig.1F-G).  
These results show an increase in mTOR activity in TAM in several mouse models of GBM, 
which is specific to TAM-MG and not observed in TAM-BMDM in the GL261 model. 
 
Glioblastoma initiating cells increase mTOR signalling via PI3K/AKT axis in tumour-
conditioned microglia but not BMDM. 
Next, we asked how mTOR deregulation occurred in TAM-MG and whether glioblastoma 
initiating cells (GIC) could play a role, considering that they secrete growth and inflammatory 
factors that could potentially stimulate mTOR signalling in microglia (Okawa et al, 2017). We 
tested this hypothesis in an in vitro setting, where primary microglia and bone marrow-derived 
macrophages (BMDM), harvested from both neonatal and 3 month-old C57BL/6 mice, were 
conditioned with the supernatant from different primary patient-derived GIC lines. Conditioned 
media was obtained from GL261 (GL261-CM) and primary Pten-/-;p53-/- mGIC cultures 
(mGICPten-/-;p53-/--CM), two models with increased mTOR signalling in TAM-MG in vivo (Fig.1B-
G). The secretome of mouse neural stem cells (mNSC-CM) derived from syngeneic mice was 
used as a control (Fig.2A). Unconditioned microglia and BMDM cultures were also used as 
controls (Fig.2A). 
mTORC1 specifically phosphorylates S6 at S240/244 and 4EBP1 at T37/46. Microglia 
conditioned with mGICPten-/-;p53-/--CM or GL261-CM showed a significant increase in 
phosphorylation at both of these sites (Fig.2B and D, Fig.EV1A), when compared to cultures 
treated with mNSC-CM or unconditioned media, supporting the notion that the phenotype is 
consistent across glioblastoma models. Conversely, BMDM displayed no difference in p-S6 or 
p-4EBP1 levels in cultures treated with mGICPten-/-;p53-/--CM or GL261-CM, compared to mNSC-
CM or unconditioned media (Fig.EV1C and E). Flow cytometry analysis of these cultures 
confirmed the increase in p-S6 (Fig.2C, Fig.EV1B) and p-4EBP1 (Fig.2E, Fig.EV1B) levels in 
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mGICPten-/-;p53-/--CM treated microglia but not BMDM (Fig.EV1F) compared to the mNSC-CM 
treatment (normalised to unconditioned cultures). Increased phosphorylation of the upstream 
regulator AKT at S473 sites in microglia (Fig.2F, Fig.EV1A) but not BMDM (Fig.EV1C and E) 
treated with mGICPten-/-;p53-/--CM or GL261-CM demonstrated increased activity of mTORC2 
signalling. Treatment with Torin (inhibitor of mTORC1 and mTORC2) resulted in significant 
reduction p-AKT (S473) in tumour-conditioned microglia (Fig.2F, Fig.EV1A), a finding which was 
validated by FACS (Fig.2G, Fig.EV1B and F). Increased phosphorylation of AKT at T308 site 
was also detected (Fig.2H). Treatment with the PI3K inhibitor (LY294002) resulted in significant 
reduction in p-AKT (T308) as well as p-S6 (S240/244) in mGICPten-/-;p53-/-- and GL261-conditioned 
microglia (Fig.2H-I, Fig.EV1A-B) but not in BMDM (Fig.EV1D-F), thereby confirming activation 
of mTOR signalling via PI3K/AKT in tumour-conditioned microglia.  
These results show that factors secreted by mGICPten-/-;p53-/-and GL261 cultures upregulate 
mTORC1 and mTORC2 signalling via the PI3K/AKT axes in microglia but not in BMDM. 
 
Genetic inhibition of mTORC1 signalling in Cx3cr1+ TAM reduces tumour growth and 
survival. 
To investigate the functional role of activated mTOR signalling in TAM-MG, genetic inhibition 
was established in these cells in mice recipient of GL261 GBM allografts (Fig.3A). The GL261 
cell line was chosen to generate fast-growing orthotopic syngeneic GBM models in 
immunocompetent mice. A mouse line with a floxed exon 3 of the Rheb1 gene (Rheb1fl/fl), a key 
effector of mTOR, was chosen to inactivate the pathway in TAM. Genetic modulation of mTOR 
signalling in vivo was achieved by crossing the Rheb1fl/fl mice with Cx3cr1-CreERT2 knock-in 
mice, resulting in deletion of Rheb1 in microglia upon Tamoxifen-induced Cre expression. Three 
weeks after tamoxifen injection, GL261 tumour cells were injected intracerebrally in mutant 
animals as well as in controls lacking the Cre construct but which also had received Tamoxifen 
treatment (Fig.3A). Mice were culled when symptomatic and a longer survival was observed for 
the Cx3cr1- Rheb1Δ/Δ mice as compared to the Rheb1fl/fl mice (Fig.3B). An independent cohort of 
allografted mice was generated and imaged 20 days post-tumour initiation by MRI. In this cohort 
measurement of tumour volume confirmed that tumours were significantly smaller in the Cx3cr1-
Rheb1Δ/Δ compared to Rheb1fl/fl mice (Fig.3C). The experiment was terminated 25 days post-
tumour initiation and the brains either processed for histology (n=5) or analysed by flow 
cytometry (n=6). Histological features were those of a highly cellular glial tumour with prominent 
nuclear pleomorphism, brisk mitotic activity and multifocal microvascular proliferations (Fig.3D). 
While no histological differences were noted between the two genotypes (Fig.3D), the numbers 
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of GL261 GFP+ tumour cells were lower in the Cx3cr1-Rheb1Δ/Δ tumours (Fig.3E), consistent 
with the reduced tumour volume observed by MRI.  
Overall 98% of TAM-MG were positive for YFP, the expression of which was dependent on Cre 
expression in Cx3cr1-Rheb1Δ/Δ mice (Fig.EV2A-C). Additionally, 35% of TAM-BMDM expressed 
YFP (Fig.EV2A-C), in accordance with the known expression pattern of the Cx3cr1 promoter in 
these tumours (Bowman et al., 2016). mTOR inhibition was confirmed in the tumours by 
assessing the expression levels of p-S6 in P2RY12+ CD49d- TAM-MG and P2RY12- CD49d+ 
TAM-BMDM by flow cytometry. We observed that p-S6 baseline levels in Rheb1fl/fl tumours 
were higher in TAM-MG than TAM-BMDM and these were significantly reduced in TAM-MG but 
not in TAM-BMDM in Cx3cr1-Rheb1Δ/Δ tumours (Fig.EV2A-C). A clear reduction in the number 
of Iba1+ p-S6+ cells was also seen in the Cx3cr1-Rheb1Δ/Δ versus Rheb1fl/fl tumour tissues 
(Fig.EV2D-E) 
The above data show that inactivation of mTORC1 in TAM reduces tumour growth and 
increases survival in a GBM mouse model. 
 
Genetic inhibition of mTORC1 signalling in TAM affects the innate/adaptive immune 
system crosstalk in GL261 tumours. 
To further characterise the phenotype observed in Cx3cr1-Rheb1Δ/Δ GL261 model, we analysed 
the transcriptome of these tumours. Principal component analysis revealed distinct clustering of 
Cx3cr1-Rheb1Δ/Δ GL261 allografts (n=3) from Rheb1fl/fl tumours (n=3) (Fig.EV3A). 425 genes 
were identified as differentially expressed between the two genotypes, the majority of which 
(302) were downregulated in Cx3cr1-Rheb1Δ/Δ tumours, with only 123 upregulated (Fig.EV3B). 
IPA analysis identified pathways associated with antigen presentation and innate to adaptive 
immune cell communication as enriched, including: dendritic cell maturation, antigen 
presentation pathway, communication between innate and adaptive immune cells, iCOS-iCOSL 
signalling, OX40 signalling, CD28 signalling, and crosstalk between dendritic cells and natural 
killer cells (Fig.4A). Csf1r and Csf1 were amongst the downregulated genes, as well as markers 
of TAM including Aif1 (Iba1) and Itgam (Cd11b), suggesting a change in the activity profile of 
TAM as a result of mTOR inhibition or a change in the immune composition of infiltrating 
immune cells (Fig.EV3C). Moreover, pathways associated with cytokine signalling were also 
detected, including: IL-4, IL-10, IL-6, IL-2, IL12 signalling, STAT3 pathway, NF-ĸB signalling, 
iNOS signalling, Interferon signalling, and toll-like receptor (TLR) signalling (Fig.4A). Amongst 
the top scoring pathways, several were associated with regulation of T cell signalling, 
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differentiation and activation – including ‘T helper cell differentiation’, ‘Th1 and Th2 activation 
pathway’, ‘T cell exhaustion signalling’, ‘PD-1, and PD-L1 cancer immunotherapy pathway’ 
(Fig4A, Dataset EV2). Amongst the differentially expressed genes, CD274 (PD-L1) was 
downregulated in the Cx3cr1-Rheb1Δ/Δ compared to Rheb1fl/fl GL261 tumours, further 
highlighting a reduced level of T cell inhibition via checkpoint inhibitors in the TME (Fig.EV3C). 
These data show that mTOR-inhibition in Cx3cr1+ TAM reshapes the immune landscape of the 
TME by influencing the expression of inflammatory mediators as well as the crosstalk between 
the innate and adaptive immune system. 
The deregulation of these immune-related pathways prompted us to further study the 
composition of the immune infiltrates in the TME of Cx3cr1-Rheb1Δ/Δ GL261 allografted 
tumours. We performed cell-type identification by estimating relative subsets of RNA transcripts 
(CIBERSORT) (Newman et al, 2015), a computational approach which accurately predicts the 
relative fraction of different cell subsets from gene expression profiles of complex tissues 
(https://cibersort.stanford.edu/index.php). When comparing the cellular fractions between the 
Cx3cr1-Rheb1Δ/Δ and Rheb1fl/fl GL261 tumours, a significant increase in CD8 cytotoxic T 
lymphocytes (CTL) and CD4 helper T (Th) cells was detected, with no changes in regulatory T 
(Treg) cells (Fig.EV3D). The monocyte cell fraction was also significantly increased. However, 
the analysis did not allow us to differentiate between monocytes, TAM-BMDM and TAM-MG. To 
validate the CIBERSORT findings and further characterise the TAM population, the immune 
composition of Cx3cr1-Rheb1Δ/Δ Rheb1fl/fl GL261 tumours was analysed by flow cytometry. This 
revealed a shift in the TAM population in the Cx3cr1-Rheb1Δ/Δ tumours, with a significant 
decrease in TAM-MG (CD45+ P2RY12+ CD49d-), while significantly higher numbers of TAM-
BMDM (CD45+ P2RY12- CD49d+) were observed (Fig.4B). The lymphocyte fraction showed an 
increase in CD8 CTL (CD45+ CD3+ CD8+) and CD4 Th cells (CD45+ CD3+ CD4+) in the Cx3cr1-
Rheb1Δ/Δ tumours (Fig.4C). Quantification of immunolabelled cells in situ confirmed increased 
CD8+ CTLs and CD4+ Th cells, with FoxP3+ Treg cell numbers remaining unchanged in the 
Cx3cr1-Rheb1Δ/Δ tumours (Fig.4D).  
Taken together these data raise the possibility that downregulation of mTOR signalling in TAM-
MG impairs proliferation or recruitment of these cells while increasing that of peripheral immune 
infiltrates, including both monocyte-derived macrophages and effector T cells. 
 
Genetic inhibition of mTORC1 signalling in TAM increases proliferation and effector 
function of CD4 and CD8 T cells in GL261 tumours. 
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Having identified changes in the tumour immune landscape, we next characterised the activity 
profile of the infiltrating lymphocytes. To this end, we comparatively analysed immune cell 
fractions, as determined by CIBERSORT, with the enrichment score of specific immune 
pathways identified in bulk tumour tissue (Fig.5A, Table EV1). A differential correlation score 
was calculated between the Cx3cr1-Rheb1Δ/Δ and Rheb1fl/fl GL261 tumours (Fig.5A). As 
expected, mTOR signalling negatively correlated with TAM with the Cx3cr1-Rheb1Δ/Δ 
background (Appendix Figure S2). Moreover, the ‘negative regulation of lymphocytes’ pathway, 
which also negatively correlated with neutrophils and TAM, clustered with mTOR signalling and 
not with other pathways. This suggests a shift in the regulation of T cell activity by TAM with an 
increased stimulatory capacity driven by mTOR inhibition. Additional support for this 
interpretation is provided by the observation that the ‘negative regulation of lymphocytes’ 
pathway negatively correlated with the CD8 CTL, Tregs and CD4 lymphocyte fractions (Fig.5B, 
Pearson correlation scores can be found in Table EV2), while the ‘Antigen Presentation’ 
pathway correlated positively. These findings suggest a change in the regulation of T cell 
activity in the TME upon downregulation of mTOR in TAM from an immunosuppressive to 
increased effector function. 
To validate the CD4/CD8 T cell enhanced effector function, as suggested by the in silico 
analysis, we analysed the expression of IFNγ, perforin and granzyme b in the tumour infiltrating 
lymphocyte populations by flow cytometry. An increased expression of perforin and IFNγ was 
detected in CD4 Th cells (Fig.5C) and an increase of perforin and granzyme b was detected in 
CD8 CTL (Fig.5D). Furthermore, to assess whether changes in T cell levels in TME of Cx3cr1-
Rheb1Δ/Δ tumours were due to infiltration and/or proliferation, we examined the expression of 
Ki67 and of adhesion molecules CD44 and CD62L. CD8 CTL and CD4 Th cells displayed 
increased proliferation with significantly higher Ki67 levels (Fig.5C-D). Moreover, both T cell 
populations displayed an increase in CD44 expression (Fig.5E) that correlated with a decreased 
CD62L expression (Fig.5F) in Cx3cr1-Rheb1Δ/Δ compared to Rheb1fl/fl tumours. This indicates 
an increase in infiltration as well as antigenic stimulation of T cells, with an increase in 
memory/effector versus naïve T cells, which results from mTOR inhibition in Cx3cr1+ TAM. 
These data are in keeping with TAM inhibiting infiltration, proliferation and function of effector T 
cells via the mTOR pathway, in a GBM mouse model. 
 
mTORC1 inhibition in TAM-MG induces a pro-inflammatory tumour microenvironment in 
GL261 allografts. 
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To understand the molecular mechanism underpinning the change in T cell infiltration, 
proliferation and effector activity observed in Cx3cr1-Rheb1Δ/Δ GL261 allografted tumours, we 
analysed the transcriptomic profile of Rheb1Δ/Δ TAM-MG (n=3) as compared to Rheb1fl/fl TAM-
MG (n=2). TAM-MG were isolated from the tumour bulk as the CD45LOW CD11b+ population by 
FACS (Fig.EV2A). As expected, a high enrichment score for the TAM-MG signature (Bowman 
et al., 2016) was detected in these cells, confirming the purity of the sorted TAM-MG population 
(Fig.EV4A). Principal component analysis revealed distinct clustering of Rheb1Δ/Δ from Rheb1fl/fl 
TAM-MG (Fig.EV3A) with 988 genes differentially expressed between the two genotypes: 823 
genes were upregulated in Rheb1Δ/Δ TAM-MG, and only 165 were downregulated (Fig.EV4B). 
IPA analysis identified enriched pathways associated with inflammatory signalling including: 
cytokine signalling pathways, such as IL-12, IL-6 and IL-8 signalling; pathways linked to 
production of nitric oxide (NO) and reactive oxygen species (ROS); receptor signalling 
pathways, such as pattern recognition receptors (PRR) and toll like receptors (TLR); and 
pathways linked to signalling in granulocytes and antigen-presenting cells (APCs), including 
Granulocyte adhesion and Diapedesis, Dendritic cell maturation, and Granzyme A signalling 
(Fig.6A, Dataset EV2). Amongst the top scoring pathways, several were associated with the 
regulation of T cell signalling and differentiation, in agreement with our observations from the 
bulk tissue transcriptome. When examining the differentially deregulated genes identified in 
these pathways, the majority of genes across all pathways were found to be upregulated 
(Fig.6A), raising the possibility that these pathways could be under co-ordinated regulation. 
To characterise the mechanistic basis for the increased number of T effector cells, we looked 
more closely at the differentially regulated genes in Rheb1Δ/Δ TAM-MG. Amongst downregulated 
genes, the chemokines Ccl5 and Cxcl13 were most frequently associated with the enriched 
canonical pathways. Amongst upregulated genes, NF-ĸB signalling (Nf-ĸb1), PI3K class I and II 
signalling (Pik3cg, Pik3c2b), as well as type I interferon signalling (Ifnar1, Tlr4) were identified 
as most frequently deregulated (Fig.6B). When looking at upstream regulators (predicted by IPA 
as potentially responsible for the observed transcriptomic profile), the majority were associated 
with interferon signalling (Fig.6C). These included interferon-regulatory factors (Irf), members of 
the Stat family of transcription factors, as well as interferon receptors. Furthermore, Isg15 and 
Usp18, inhibitors of type I interferon signalling, were amongst the few significantly 
downregulated genes (Fig.EV4C). Importantly a predicted upregulation of NF-ĸB signalling was 
detectable (Fig.EV4D). Interestingly, several of the signalling pathways identified as deregulated 
in Rheb1Δ/Δ TAM-MG, were found to be significantly deregulated in GL261 TAM-MG but not in 
TAM-BMDM, including IFN signalling, NF-kB and STAT3 signalling (Fig.EV4E).  
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To gain further support for a regulatory role of mTOR signalling on these signalling pathways, a 
Pearson correlation analysis was run between the ssGSEA enrichment score of deregulated 
pathways in the Rheb1Δ/Δ TAM-MG. The enrichment of mTOR signalling positively correlated 
with the enrichment of the ‘negative regulation of lymphocytes’ signature, whist they both 
negatively correlated with NF-ĸB and IFNγ signalling as well as ‘Leukocyte differentiation’, ‘Th1 
and Th2 differentiation’, and ‘T cell chemotaxis’ signatures (Fig.6D).   
Therefore, our data suggest that inhibition of mTOR in TAM-MG remodels the immune 
composition of the microenvironment and increases the presence of effector T cells through the 
upregulation of pro-inflammatory related pathways, including IFNγ and NF-kB signalling.  
 
mTOR-dependent expression of inflammatory cytokines in tumour–conditioned microglia 
promotes an anti-inflammatory phenotype via the regulation of STAT3 and NF-ĸB 
transcription factors. 
Next, we set out to validate the in silico prediction from the in vivo transcriptomic profile of 
Rheb1Δ/Δ TAM-MG that mTOR signalling negatively regulates NF-ĸB in TAM-MG, and is 
responsible for the immunosuppressed phenotype in GBM. In addition, to test for a possible 
contribution of the STAT family of transcription factors, we assessed STAT3 activity. STAT3 has 
been previously reported as deregulated in GBM TAM, and associated with expression of anti-
inflammatory cytokines, contributing to an immunosuppressed TME (West et al, 2018; Wu et al, 
2010). Moreover, it has been shown to regulate the inflammatory activity of monocytes in 
response to infection in an mTOR-dependent manner (Weichhart et al, 2008).  
We used our in vitro experimental system (Fig.2A) to assess whether the mTOR-dependent 
activity of these transcription factors was responsible for the pro-inflammatory profile of TAM-
MG. While no changes in p-NF-ĸB (p-P65) levels were detected in tumour-conditioned BMDM 
(using mGICPten-/-;p53-/--CM as well as GL261-CM) (Fig.EV4G), we observed a slight increase 
phosphorylation of NF-ĸB (p-P65) in tumour-conditioned microglia, an effect enhanced by 
mTOR inhibition (Fig.6E, Fig.EV4F). To further validate the mTOR-dependent regulation of NF-
ĸB (P65), nuclear localisation of this transcription factor was assessed in tumour-conditioned 
microglia and BMDM. While mGICPten-/-;p53-/--CM increased nuclear localisation of NF-ĸB (P65) in 
microglia, mGL261-CM had no effect compared to mNSC-CM (Fig.6F). However, mTOR 
inhibition (using Torin) combined with tumour conditioning (mGICPten-/-;p53-/--CM or GL261-CM) 
significantly increased the nuclear translocation of NF-ĸB (P65), compared to NSC-CM and 
tumour-conditioning alone (Fig.6F). BMDM displayed no difference in nuclear localisation of NF-
ĸB (P65), under any condition (Fig.EV4H). In keeping with this finding, IL-12 expression was 
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increased only upon treatment with Torin. Moreover, TNF, another cytokine regulated by NF-ĸB, 
was upregulated by mGIC-CM in an mTOR-independent fashion (Fig.6G). We also observed 
increased phosphorylation of STAT3 in microglia treated with mGIC-CM and GL261-CM, an 
effect which was lost upon inhibition of mTOR signalling by Torin, as assessed by western 
blotting (Fig.6E, Fig.EV4F) and flow cytometry (Fig.EV4I). Once again, this effect was not 
observed in tumour-conditioned BMDM with mGICPten-/-;p53-/--CM or GL261-CM (Fig.EV4G). 
Importantly, upregulation of IL-10 and IL-6 was observed in microglia treated with mGIC-CM, as 
predicted given the increased p-STAT3. However, it was not observed under mTOR inhibition 
(Fig.6G), in accordance with the expression of anti-inflammatory cytokines IL-10 and IL-6 being 
mediated by mTOR-dependent regulation of STAT3 activity. Moreover, P2RY12+ CD49d- TAM-
MG but not P2RY12- CD49d+ TAM-BMDM expressed significantly lower levels of p-STAT3 
(Fig.6H) and higher levels of p-NF-ĸB (p-P65) in Cx3cr1-Rheb1Δ/Δ allografts (Fig.6I), validating 
our in vitro findings. 
In conclusion, increased phosphorylation of STAT3 in tumour-conditioned microglia upregulates 
the expression of IL-10 and IL-6 in an mTOR-dependent fashion with a concomitant reduction in 
expression of IL-12 mediated by reduced phosphorylation and nuclear translocation of NF-κB.  
 
Enrichment of mTOR signalling correlates with TAM-MG and a negative regulation of T 
cells in TCGA GBM samples. 
In order to assess the translational value of our findings in human glioblastoma, we took 
advantage of the TCGA dataset, a publicly available database with transcriptomic data for tissue 
bulk from 138 IDH-wildtype GBM. To extract information specific to TAM from bulk sequencing, 
we carried out a correlation analysis between the mTOR pathway and TAM-MG or TAM-BMDM 
gene expression signatures. Using single sample gene set enrichment analysis (ssGSEA) 
(Barbie et al., 2009), enrichment scores were calculated for each patient for pre-defined 
signatures of mTOR signalling, as well as TAM-MG and TAM-BMDM. TAM-MG and TAM-
BMDM signatures have been previously characterised (Bowman et al., 2016) and the mTOR 
signature was obtained from the mSigDB database (Table EV1). A significant positive linear 
correlation was found between the enrichment score for the mTOR signature and the TAM-MG 
signature but not for the TAM-BMDM signature (Fig.7A, Table EV3). IDH-wildtype GBM were 
then further grouped according to their molecular profiles using the transcriptional classification 
of Wang et al. (Wang et al., 2017). The positive correlation between mTOR and TAM-MG 
signatures was most significant in the Mesenchymal subgroup and not present in the Proneural 
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subgroup (Fig.7A, Table EV3). These results were replicated in an additional dataset 
(Fig.EV5A). 
Next, we used the TCGA dataset to assess the impact of this mTOR signature on TAM-MG 
phenotype and on the immune composition of the tumours. We separated tumours into those 
with the signature (group 1: positive mTOR and microglia enrichment, displayed in orange) and 
those without the signature (group 2: displayed in green) (Fig.7B). A CIBERSORT analysis was 
run on these two groups to identify any differences in their immune composition. The first 
striking result was that the two groups displayed contrary immune composition (Fig.7C), with 
GBM in group 1 showing more Tregs, CD4 naïve and memory resting cells and less CD8 CTL 
and CD4 memory activated cells, whilst GBM in group 2 displayed the opposite pattern (Fig.7C). 
Importantly, the low level of CD8 CTL and CD4 memory activated cells in GBM with the mTOR 
signature is reminiscent of our findings in GBM mouse models with the signature. 
To gain additional evidence for the observed difference in immune cell composition between the 
tumour groups being driven by mTOR signalling in TAM-MG, we looked at the signalling activity 
of TAM-MG compared to TAM-BMDM in GBM from group 1. We correlated the enrichment of 
TAM-MG and TAM-BMDM (using the Bowman et al. gene signature) with that of signalling 
pathways identified as mTOR-dependent in the mouse model, including NF-ĸB, STAT3, IFNγ, 
‘Th1/Th2 differentiation’, ‘T cell chemotaxis’, ‘antigen presentation’, and the ‘negative regulation 
of lymphocytes’ (Fig.7D). The mTOR pathway and the ‘negative regulation of lymphocytes’ 
emerged as a separate cluster. In TAM-MG, the mTOR pathway and the ‘negative regulation of 
lymphocytes’ were positively correlated while the other pathways were negatively correlated, in 
accordance with our findings in mouse models (Fig.7D). While TAM-BMDM enrichment 
positively correlated with mTOR as well, correlation with the rest of the signatures did not follow 
the same pattern as observed in the mouse model, for example a negative correlation was 
found with the ‘negative regulation of lymphocytes’ (Fig.7D). 
These data confirm that a positive correlation between deregulation of mTOR signalling and 
TAM-MG but not TAM-BMDM is also found in human GBM. These data also show that GBM 
with the signature (high mTOR and microglia enrichment) display stronger depletion of activated 
lymphocytes compared to GBM without the signature, a phenotype potentially driven by mTOR-
dependent TAM-MG activity.  
 
mTOR signalling is deregulated in iMGL treated with syngeneic human GIC-CM. 
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To assess the functional relevance in human GBM of the findings in mouse models and of the in 
silico TCGA data, a GBM syngeneic induced EPSC-derived microglia-like (iMGL) cell model 
was established (Fig.7E).  
Two human GIC lines (hGIC), were used. They were both derived from IDH-wild type GBM 
tissue according to standard protocols (Pollard et al, 2009), and confirmed to belong to the 
Mesenchymal subgroup by DNA methylation array (Illumina 450 K) on bulk tumour as well as on 
GIC, followed by classification on the Heidelberg classifier (Capper et al, 2018) (Table EV4). 
Patient-matched fibroblasts derived from the dura mater of the same patients were 
reprogrammed to EPSC (Gao et al, 2019; Yang et al, 2019) and iMGL were generated 
according to published protocols (Muffat et al., 2016) (Fig.EV5B). To confirm the progression of 
the differentiation process, cells were analysed by flow cytometry at different stages for markers 
of stemness, early yolk sac myelogenesis and mature microglia (Muffat et al., 2016; Abud et al., 
2017; Douvaras et al., 2017; Pandya et al., 2017). Expression of Sox2 and Nanog was 
confirmed in EPSC while all other markers were negative (Fig.7F, and Fig.EV5C). Yolk-sac 
embryoid bodies (YS-EBs) no longer expressed these stemness markers while gaining 
expression of CD41, c-kit, CD235a, and PU.1, previously described as expressed before 
definitive haematopoiesis or the establishment of embryonic circulation (<E8.5) (Fig.7F, and 
Fig.EV5C). Markers specific to microglia, P2RY12, Iba1 and TMEM119 were upregulated in 
mature iMGL (Fig.7F, and Fig.EV5BC) and complete differentiation was confirmed by 
immunocytochemistry for PU.1 and CD11b (Fig.7G) and double-labelling immunofluorescence 
for Iba1 and TREM2 (Fig7H). Moreover, CD49d expression, specific to monocyte-derived 
macrophage, was not detected in the differentiated iMGL (Fig.7F, and Fig.EV5C). 
Next, hGIC conditioned media was applied to the syngeneic EPSC-iMGL. Conditioned media 
from the syngeneic EPSC (from which the iMGL were differentiated; EPSC-CM) was used as a 
control. Similar to our findings in the mouse setting, p-S6 (S240/244) was upregulated by hGIC-
secreted factors (Fig.7I, Fig.EV5D). Furthermore, increased p-STAT3 levels were detected in 
iMGL upon treatment with hGIC-CM and the effect was mTOR-dependent, as shown by p-
STAT3 levels returning to basal levels upon Torin treatment (Fig.7J, Fig.EV5D). A trend toward 
an increase in p-NF-kB (p-P65) was also observed under hGIC-CM treatment, although not 
significant. Importantly, levels of p-NF-kB (p-P65) were significantly increased under hGIC-CM 
and Torin treatment (Fig.7K, Fig.EV5D). Treatment with EPSC-CM had no effect on the 
phosphorylation levels of these markers. 
To validate in a human in vitro setting that this phenotype is microglia specific and not observed 
in peripheral macrophages, we analysed mTOR signalling in tumour-conditioned peripheral 
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blood monocytes/macrophages, obtained from healthy donor (Appendix Figure S3A). The 
phosphorylation levels of S6 (Appendix Figure S3B), STAT3 (Appendix Figure S3C) as well as 
NF-B (Appendix Figure S3D) remained unchanged in CD49d+ human 
monocytes/macrophages treated with EPSC-CM or hGIC-CM, validating the microglia-specific 
effect of GIC secreted factors on mTOR signalling. 
We show in a novel syngeneic in vitro model that iMGL conditioned with hGIC-CM upregulate 
mTOR, and that this impacts STAT3 and NF-kB activity in a similar fashion to that found in 
murine models. 
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Discussion 
 
We show that GIC induce mTOR signalling in TAM-MG but not TAM-BMDM in in vivo and in 
vitro mouse models of GBM as well as in a human GIC/iMGL in vitro assay. The mTOR-
dependent regulation of STAT3 and NF-ĸB activity promotes an immunosuppressed phenotype 
in TAM-MG, which hinders effector T cell proliferation and immune reactivity and contributes to 
tumour immune evasion.  
We describe increased mTOR signalling in TAM-MG but not in TAM-BMDM in mouse models of 
GBM. mTOR signalling positively correlates with TAM-MG enrichment in human GBM samples 
but not with TAM-BMDM at the transcriptomic level, supporting the translational relevance of our 
findings in mouse models. Our data implies that ontogeny affects the way microglia and 
monocyte-derived macrophages respond to GIC secreted factors, which extends previous work 
showing that the transcriptomic profiles of TAM-MG and TAM-BMDM differ when exposed to the 
same tumour microenvironment (Bowman et al., 2016; Muller et al, 2017).  Recent reports have 
identified mixed transcriptional states in the TAM population in glioma patients (Gabrusiewicz et 
al, 2016; Szulzewsky et al, 2016; Szulzewsky et al., 2015), and here we identify mTOR 
signalling as a key driver of this intra-tumoural TAM heterogeneity.  
We demonstrate that the pro-tumourigenic role of TAM-MG in GBM is mediated by mTOR, as 
reduced tumour growth and increased survival was observed upon genetic silencing of the 
pathway in these cells in GL261 allografts. Although a contribution to the observed phenotype 
by the small proportion of TAM-BMDM also targeted by the Cx3cr1-Cre driver cannot be entirely 
excluded, it seems unlikely as both the transcriptomic analysis in the in vivo model and the 
signalling analysis in the in vitro model highlight the lack of significant mTOR activity in TAM-
BMDM. The transcriptomic profile of Cx3cr1-Rheb1Δ/Δ tumours demonstrated a shift in the 
immune landscape with an overall decrease in the negative regulation of T cells in the TME and 
a change in T cell state from an exhausted to an active profile, suggesting a capacity to mount 
an anti-tumour adaptive immune response. This is further demonstrated by a change in the 
immune composition of Cx3cr1-Rheb1Δ/Δ tumours, defined by reduced numbers of microglia 
while immune cells that have infiltrated from the peripheral circulation are more numerous, 
including effector T cells and TAM-BMDM. Transcriptomic analysis of Rheb1Δ/Δ GL261 TAM-MG 
revealed a re-education of these cells to an immune reactive and anti-tumour profile, with an 
enrichment for pathways linked to the regulation of Th1, Th2 and IFN signalling as well as 
pathways linked to recruitment, proliferation and priming of APC and cytokine signalling 
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pathways. The predicted impact of this transcriptional deregulation is an increase in the 
stimulation of the adaptive immune system by innate immune cells and consequently an 
increase in effector and cytotoxic T cells within the tumour; an effect which was confirmed by 
tissue and flow cytometry analyses, which revealed an increase in CD4+ and CD8+ T cells, and 
no significant changes in FoxP3+ cells in the Cx3cr1-Rheb1Δ/Δ TME as well as an increase in 
infiltration, proliferation and effector function of CD4+ and CD8+ T cells. 
 
GBM are lymphocyte depleted with a high infiltration of TAM (Mirzaei, Sarkar and Yong, 2017; 
Thorsson et al., 2018; Woroniecka et al., 2018). Within the tumour-infiltrating lymphocytes, 
Tregs are the most numerous population and can suppress T helper cell and CTL responses (El 
Andaloussi and Lesniak, 2006; Mirzaei, Sarkar and Yong, 2017), whilst CD8+ and CD4+ T cells 
are exhausted (Thorsson et al., 2018; Woroniecka et al., 2018). Moreover, CD8+ and CD4+ T 
cells which do infiltrate the tumour seem unable to mount an anti-tumour effector response in 
GBM (Learn et al., 2006). T cell exhaustion is known to result from an excessive and continuous 
stimulation by APC and cytokines, resulting in sustained expression of inhibitory receptors and 
the lack of a productive anti-tumour effector response (Mirzaei, Sarkar and Yong, 2017). TAM 
contribute to T cell dysfunction in GBM via their immunosuppressed phenotype, characterised 
by reduced expression of pro-inflammatory factors, antigen-presenting machinery and T cell 
activation factors (Poon et al., 2017). In our Cx3cr1-Rheb1Δ/Δ model, T cell effector profiles were 
stimulated, as shown by the increased proliferation and expression of cytotoxic factors such as 
IFN, granzyme-b and perforin, in keeping with a scenario where mTOR significantly contributes 
to TAM-mediated T cell dysfunction in GBM. Moreover, a distinct deregulation of cytokine 
signalling pathways was identified in our Cx3cr1-Rheb1Δ/Δ model, most notably those regulated 
by STAT3 (anti-inflammatory cytokines) and NF-ĸB (pro-inflammatory cytokines). The survival 
benefits of STAT3 inhibition has been shown in a GL261 model, where the expression of 
cytokines promoting tumour growth, such as IL-10 and IL-6, was blocked (Zhang et al., 2009). 
Further work by Hussain et al. illustrates the potential effect of these STAT3-regulated 
cytokines, expressed by TAM, on the proliferation of effector T cells and TCR-mediated 
signalling (Hussain et al., 2007). Importantly, STAT3 is upregulated in TAM in human GBM and 
considered an attractive therapeutic candidate (Heimberger and Sampson, 2011; Wei, 
Gabrusiewicz and Heimberger, 2013; Chang et al., 2017; Poon et al., 2017). We show here that 
mTOR signalling increases STAT3 activity and inhibits NF-ĸB in TAM-MG in different GBM 
models, therefore hampering APC immune re-activity as well as effector T cell proliferation and 
immune response via the expression of anti-inflammatory cytokines. 
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In our study, we have taken advantage of methodologies to derive induced microglia (iMGL) 
from EPSC (Muffat et al, 2016) to develop a new in vitro assay. GIC were established from 
human GBM, and hGIC-CM obtained therefrom were incubated with the syngeneic iMGL to 
assess the relevance of the results of our mouse models in humans on a patient-specific basis. 
mTOR signalling positively correlated with TAM-MG enrichment but not with TAM-BMDM at 
transcriptomic level in the TCGA samples, a finding that was most prevalent in Mesenchymal 
tumours, and thus we applied the assay to hGIC/iMGL derived from GBM classified as 
belonging to the Mesenchymal subtype. We reason that as no significant differences in the 
levels of TAM-MG were previously observed across the molecular subgroups (Bowman et al., 
2016), the strong correlation we observed in Mesenchymal GBM was not due to a higher 
number of TAM-MG in this subgroup. We showed that hGIC derived from Mesenchymal GBM 
triggered activation of mTOR signalling in iMGL and mTOR-dependent regulation of STAT3 and 
inhibition of NF-ĸB signalling, in line with our findings in mouse models. Interestingly, a key 
characteristic of the Mesenchymal subgroup of GBM is its strong association with immune-
related genes and an enrichment of infiltrating immune cells (Behnan et al, 2019; Chen & 
Hambardzumyan, 2018), thereby raising the possibility that Mesenchymal-specific features of 
the hGIC phenotype might be responsible for inducing mTOR signalling in TAM-MG. 
 
We demonstrate that GIC secreted factors are sufficient to increase mTOR activity in microglia, 
although this does not exclude the possibility that factors secreted by other cells, including non-
GIC tumour cells, may contribute to this phenotype. The secretome of GIC has been 
characterised (Formolo et al, 2011; Polisetty et al, 2011), but only little is known on the 
functional impact of specific secreted factors on TAM phenotypes. We show here that GIC-CM 
contains factors capable of inducing mTOR pathway activation in TAM-MG in both humans and 
mice. A study comparing conditioned media of GIC and healthy NSC identified several 
inflammatory and growth factors, including potential mTOR stimuli (Okawa et al., 2017). While it 
is likely that a combination of these factors is responsible for the phenotype, osteopontin as well 
as lactate emerge as strong candidates (Lamour et al, 2010; Okawa et al., 2017). Osteopontin 
acts via several integrins known to influence PI3K/AKT/mTOR signalling (Ahmed & Kundu, 
2010). It regulates migration, phagocytosis, as well as the expression of inflammatory factors in 
microglia (Yu et al, 2017), including in a GBM context (Ellert-Miklaszewska et al, 2016; Wei et al, 
2019). Osteopontin expression correlates with poorer survival in GBM (Atai et al, 2011; Wei et 
al., 2019) and its expression is enriched in Mesenchymal as compared to Classical and 
Proneural tumours (Wei et al., 2019). Strikingly, remarkably similar findings to those seen in our 
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mouse model were described in the TME of a GL261 allograft GBM model upon depletion of 
osteopontin (Wei et al., 2019). Lactate was also shown to be highly expressed by GIC and has 
been proposed as a prognostic marker for GBM (Marchiq & Pouyssegur, 2016). It contributes to 
acidification of the TME, which polarises TAM (Colegio et al, 2014; Mu et al, 2018; Romero-
Garcia et al, 2016) therefore promoting immune evasion and tumour growth (Lui & Davis, 2018), 
possibly via interaction of lactate with the GPR65 receptor on TAM (Lailler et al, 2019). A study 
examining the effect of lactate and hypoxia on macrophages demonstrated an increase in 
mTOR signalling, which is suggested to be responsible for acquired M2-like phenotype with the 
inhibition of pro-inflammatory cytokines production (Zhao et al, 2019). It is therefore conceivable 
that differences in the threshold of lactate- and/or osteopontin-dependent mTOR activation in 
TAM-MG and TAM-BMDM may explain the different phenotype and function of these two 
populations in the TME.  
 
Despite the importance of the deregulation of mTOR signalling in driving GBM growth, drugs 
aimed at targeting this pathway have so far failed in clinical trials (Jhanwar-Uniyal et al., 2019). 
Our results raise the possibility that tumour cells should not be the primary target of mTOR 
inhibition. Infiltration of CD8+ and CD4+ T cells but not FoxP3+ Treg cells, as observed in our 
Cx3cr1-Rheb1Δ/Δ tumours, correlates with long-term survival in GBM patients (Abedalthagafi et 
al, 2018; Heimberger et al, 2008; Yang et al, 2010), hence providing the rationale for 
immunotherapies aimed at modifying the infiltration or immune-reactivity of the T cell population, 
such as drugs targeting inhibitory checkpoints. However, immune checkpoint inhibitors such as 
anti-CTLA-4 and anti-PD-1 antibodies have had little success as monotherapies in the treatment 
of GBM (Chen & Hambardzumyan, 2018), suggesting that blockade of immune checkpoints 
alone is not sufficient to restore anti-tumour immune functions in the GBM TME. Our 
observation that increased CD8+ and CD4+ tumour infiltrating lymphocytes, induced by mTOR-
inhibition in Cx3cr1+ TAM, correlates with reduced tumour growth supports further exploration of 
this approach and raises the possibility that precision targeting of the mTOR pathway, for 
example by nanoparticle-based drug delivery, the efficacy of which have already been 
demonstrated in liver and breast cancer (Huang et al, 2012; Singh et al, 2017), could be a viable 
approach in combination with existing T cell-targeted immunotherapies to condition the TME 
toward a pro-inflammatory state, which is potently anti-tumourigenic.  
 
  
   
 
Page 22 of 44 
 
Material and Methods  
 
In vitro cell culture 
Mouse cell cultures 
mNSC were previously derived from the subventricular zone of Ptenfl/fl;p53fl/fl C57BL/6 mice. The 
Pten-/-;p53-/- mGIC were previously generated by in vitro recombination of these Ptenfl/fl;p53fl/fl 
mNSC using adenovirus expressing Cre recombinase and confirmed as GIC following intra-
cranial injection of these cells into the striatum of non-recombined mice of similar genetic 
background, which led to the development of malignant tumours (Jacques et al., 2010). 
Ptenfl/fl;p53fl/fl mNSC and Pten-/-;p53-/- mGIC were maintained in culture as previously described, 
in DMEM/F12 medium (Gibco, 31330-038), supplemented with growth factors (B27 (2%, Gibco, 
12587-010), mEGF (20ng/ml, Preprotech, 315-09) and hFGF (20ng/ml, PreproTech, AF-100-
18B)). Culture plates were coated with poly-L-lysine (Sigma, P1524; 0.01mg/ml for 30min at 
room temperature-RT) and laminin (Sigma, L2020; 1:160 for 30min at 37°C) (Zheng et al, 2008). 
The GL261 murine glioma cells were a gift of Dr Jeffrey E. Segall in 2018 (Albert Einstein 
College of Medicine, USA). The cells were cultured in DMEM supplemented with 10% heat-
inactivated foetal bovine serum, penicillin, streptomycin and glutamine. Conditioned media was 
collected after 24 hours from 80% confluent cultures, filtered through 0.2 µm filter and stored at -
80°C. BMDM were differentiated and primary microglia isolated using standard protocols 
(Weischenfeldt & Porse, 2008) (Chen et al, 2013). Once established, BMDM and microglia were 
cultured in the same DMEM media supplemented with 1% penicillin streptomycin solution. 
 
Human fibroblasts cultures from dura mater, establishment and maintenance 
Patient consent and ethical approval was available for the study (08/H0716/16 Amendment 1 
17/10/2014). Thin strips of dura mater were sliced and triturated with a scalpel. The tissue was 
then digested with trypsin for 5 minutes at 37°C. The reaction was stopped with culture media 
(DMEM, Glutamax, 10% Foetal calf serum, 2% L-Glutamin and 1% penicillin-streptomycin). 
Samples were centrifuged and resuspended in fresh media and plated in 6-well plates (Corning 
#BC010). Media was topped up 1 week later, then changed every 48hrs. RNA and DNA were 
extracted from cell pellets using the RNA/DNA/Protein Purification Plus kit (NORGEN, #47700), 
following the manufacturer’s protocol.  
 
EPSC generation from fibroblasts cultures 
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Fibroblasts reprogramming was performed following a previously described protocol (Gao et al., 
2019; Yang et al., 2019; Yang et al, 2017). Briefly, the fibroblasts isolated from dura mater were 
mixed with episomal vectors expressing Oct4, c-Myc, Klf4, Sox2 (OCKS 4F, 5µg) and Rarg, 
Lfh1 (RL 2F, 5.0 µg), electroporated with Amaxa Nucleofector (Lonza, Germany) then plated on 
SNL feeders with M15 media (Knockout DMEM Invitrogen, 15% Fetal Bovine Serum Hyclone, 
1X Glutatamin-Penicillin-Streptomycin Invitrogen, 1X non-essential amino acids Invitrogen). 
Upon the appearance of colonies, media was replaced with EPSCM (DMEM/F12 Invitrogen, 
20% Knockout Serum Replacement Invitrogen, 1X Glutamin-Penicillin-Streptomycin, 1X non-
essential amino acids Invitrogen, 0.1 mM β Mercapto-ethanol Sigma, 106 U/ml hLIF Millipore 
supplemented with the following inhibitors: CHI99021 Tocris 1µM, JNK Inhibitor VIII Tocris 4 
µM, SB203580 Tocris 10µM, A-419259 Santa Cruz 1µM and XAV939 Stratech 1µM). Colonies 
were isolated and plated in 24 well SNL feeders’ plates for expansion and characterization. RNA 
and DNA were extracted from cell pellets using the RNA/DNA/Protein Purification Plus kit 
(NORGEN, #47700), following the manufacturer’s protocol.  
 
GIC isolation  
Patient consent and ethical approval was available for the study (08/H0716/16 Amendment 1 
17/10/2014). Fresh GBM tissue was sliced and triturated with razor blade, dissociated with 
Accumax (sigma, A7089) at 37˚C for 10 mins then filtered through a 70μm cell strainer. 
Dissociated cells were plated on laminin-coated 6-well plate in NeuroCult NS-A Proliferation kit 
media (STEMCELL, 05751), heparin (2 μg/ml; Gibco 12587-010), mEGF (20ng/ml, Prepro 
Tech, 315-09) and hFGF (10ng/ml; Prepro tech, AF-100-18B). Established cells were passaged 
when 70% confluent, frozen in Stem Cell Banker (Ambsio ZENOAQ, 11890) and stored in liquid 
nitrogen. RNA and DNA were extracted from cell pellets using the RNA/DNA/Protein Purification 
Plus kit (NORGEN, #47700), following the manufacturer’s protocol. Cell lines used in this study 
are primary lines either derived from mouse brains or human tumours, they have been 
characterised by transcriptomic profiling and cultured according to current practice, including 
contamination-screening. 
 
EPSC differentiation to iMGL 
iMGL cells were generated following Muffat et al. published protocol (Muffat et al., 2016), with 
some changes including culturing YS-EBs in oxygen-deprived environment (5% O2) as 
previously described (Abud et al, 2017). 
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In vitro stimulation of tumour-infiltrating T cells 
Following tumour tissues processing, single-cell suspensions were plated in 24well plates with 
DMEM supplemented with 1% of penicillin and streptomycin. The cultures were stimulated with 
cell stimulation cocktail (eBioscience, 00-4970) composed of PMA and ionomycin, in 
combination with the protein Transport Inhibitor cocktail (eBioscience, 00-4980). Following 
overnight incubation, the cells were collected and stained according to the intracellular flow 
cytometry protocol.  
 
Isolation of human blood-derived monocytes/macrophages 
Peripheral blood was collected from healthy volunteers. Monocytes/macrophages were purified 
from the samples using the RosetteSep Human Monocyte Enrichment Cocktail kit (StemCell, 
15028) and Lymphoprep density gradient medium (StemCell, 07801) following the manufacturer 
protocol. The highly enriched monocyte population was then cultured using RPMI culture 
medium and conditioned with conditioned media where specified in figure legends. Conditioned 
cells were then process by flow cytometry. CD49d expression was assessed for purity of the 
population. 
 
Analysis of signal transduction events 
A total of 1x106 mouse BMDMs, mouse primary microglia and iMGL per condition were treated 
and stimulated as indicated. Cells were pre-treated for 60 min with 100nM rapamycin 
(Calbiochem, 552310), 500mM Torin (Tocris, 4247), or 10µM LY294002; and then stimulated 
with 100ng/ml of LPS from E. Coli 0111:B4 (Sigma, L4391) or with mNSC-CM, mGICPten-/-;p53-/--
CM, GL261-CM. Protein analysis was carried out by western blot or flow cytometry as described 
in supplemental experimental procedures. Cytokines were analysed at RNA level. Samples for 
RNA analysis were extracted and processed following manufacturer’s protocol, using the 
Qiagen RNA extraction microkit (Qiagen, 74004) and KiCqStart SYBR Green Primers (Sigma). 
 
 
In vivo 
Mice 
All procedures were carried out according to the Home Office Guidelines (Animals Scientific 
Procedures Act 1986, PPL 70/6452 and P78B6C064). Mouse models have been previously 
reported (Bowman et al., 2016; Yona et al, 2013; Zou et al, 2011). The Cx3cr1Tm2.1CreERT2 mice, 
developed in Steffen Jung’s lab (Yona et al., 2013), were purchased from Jackson lab 
   
 
Page 25 of 44 
 
(#021160), and bread with Rheb1fl/fl mice, shared with us by Paul Worley, Johns Hopkins 
Department of Neuroscience (Zou et al., 2011). Tamoxifen (T5648, Sigma) was diluted in 100% 
ethanol at 37°C, then in sunflower seed oil (Sigma, S5007 - 10mg/ml) and injected i.p. 3 weeks 
before tumour initiation as previously described (Bowman et al., 2016). Two intraperitoneal 
injections of 1mg of tamoxifen each were administrated within 48hrs. 
 
Brain tumour models  
Intracranial injections of GL261 cells were performed 3 weeks post-tamoxifen injections as 
previously described (Bowman et al., 2016). Briefly, the animals were anesthetised using 
isoflurane and analgesic was injected prior to surgery. Using a stereotactic frame, cells were 
injected into the right frontal cortex (2mm posterior and 2mm lateral from the bregma anteriorly 
and the lambda at a depth of 2-3mm). GL261 cells were injected at a concentration of 2x104 
cells/5µl in PBS at 6 weeks of age. The animals were scarified around 3 weeks post tumour 
initiation. 
 
MRI and Quantitative Assessment of Tumour Volume 
Tumour imaging was carried out on Bruker ICON 1T preclinical MRI system using a Paravision 
software. Before the imaging experiments, mice were anaesthetised with isoflurane/O2 [4%(v/v)] 
and maintained on isoflurane/O2 [2%(v/v)] throughout the experiment. T2_rare scans were 
carried out with the following parameters: 2505ms repetition time; 85ms Echo time; 21.25ms 
Echo spacing; 11 slices 0.8mm thick each; 89x89 voxels image size; 0.191x0.191mm 
resolution; 17x17mm field view, 16 averages. Images were analysed on the VivoQuant 
software, by manually defining tumour region with 3D ROI tool. 
 
Tumour tissue processing 
For all tissue analyses, mice were anaesthetised with Euthatal and transcardially perfused with 
PBS. Tumour tissues were isolated by macrodissection and dissociated using the Brain Tumour 
Dissociation Kit (BTDK; Miltenyi, 130-095-942) and a single-cell suspension generated using 
the gentleMACSTM Dissociator. All single-cell suspensions were filtered through a 40-mM mesh 
filter. Normal brain and brain tumour tissues were incubated with Myelin Removal Beads 
(Miltenyi, 130-096-733). Cells were then counted and resuspended in flow cytometry buffer. 
Alternatively, tissues were collected following perfusion and incubated in 4% PFA for 2 days 
prior paraffin embedding or processed in 30% glucose overnight prior to freezing in OCT. 
Antibody labelling were carried out using standard protocols.  
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Immunoassay techniques 
Western blotting 
For western blot, lysate preparation and analysis was performed as previously described 
(Badodi et al, 2017; Weichhart et al., 2008). Proteins were extracted with RIPA buffer (Santa 
Cruz, sc 24948A) on ice for 45 minutes with frequent vortex. Equal amounts of proteins were 
separated by SDS-PAGE (NUPAGE 4-12% Bis acrylamide NP0335) and incubated with primary 
antibody. Vinculin was used as housekeeping protein for loading control. Results were 
visualised using a BIORAD ChemiDoc MP Imaging. Protein quantification was performed using 
Fiji image analysis software.  
 
Flow cytometry 
Following tumour tissues processing, single-cell suspensions were resuspended in FC blocked 
(CD16/32, BD #553141) on ice and then incubated with antibody master mix. After washing, the 
cells were stained with a fixable viability dye-e506 (eBioscience) in PBS. For extracellular 
staining only, cells were fixed in 2% PFA and resuspended in flow cytometry buffer. For 
intracellular staining, cells were resuspended in Foxp3 Intracellular staining kit (eBioscience) 
according to the manufacturer’s protocol. All flow cytometric analysis was performed using a BD 
LSRFortessa device, and sorting was performed on an Aria fusion, with a FACSDiva software 
Version 8. Data were transferred and analyzed using the FlowJo software V10 (Tree Star, 
Oregon, USA). 
The gating strategy employed was as followed – cells were first selected based on size using 
the FSC-A and SSC-A. Then doublets were removed from the analysis using SSC-A versus 
SSC-W and FSC-A versus FSC-H. Lastly, live cells were selected for by gating on cells 
negative for the fixable viability dye-e506. Gating for T cells employed CD45 and CD3 markers 
as well as CD4 and CD8 to define subpopulation. Gating for TAM population relied on CD11b+ 
CD45low P2RY12+ CD49d- marker expression for TAM-MG and CD11b+ CD45high P2RY12- 
CD49d+ for TAM-BMDM. 
 
Immunohistochemistry and tissue analysis 
Frozen and FFPE tumour tissues were obtained for the GL261 allograft model and the genetic 
models Ntv-a;PDGFB+Shp53, Pten-/-;p53-/-, the Pten-/-;p53-/-;Idh1R132H, PDGFB (Bowman et al., 
2016; Jacques et al., 2010; Zhang et al., 2019). The mouse samples were processed at UCL 
IQpath laboratory. Dewaxing, antigen retrieval and pre-treatment with appropriate serum was 
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performed as per published protocols (Badodi et al., 2017). One section per biological replicates 
was analysed and quantified for each mouse model and the number of biological replicates per 
mouse model is indicated in the figure legends. Stained cells were cultured and conditioned on 
coverslips. Post incubation time, the cells were fixed and permeabilise with 0.1% triton. 
Following pre-treatment with appropriate serum, cells were incubated with primary, then 
secondary antibody for 1hr each. Coverslips were mounted on slide using prolong gold anti-face 
mounting with DAPI (Life Technology, P36981). An isotype control was performed to validate 
the quenching of fluorescence from reporter gene. A Leica DM5000 Epi-Fluorescence 
microscope was used for analysis of immunocytochemistry and on Zeiss confocal 880 with Zen 
2.3 SP1 program for immunohistochemistry. Definiens Tissue Studio Software (Definiens AG) 
was used for quantification.  
 
Antibody list 
The following antibodies were used for immunoassays:  
p-S6 Ser240/244 (Cell signalling, 5364 and 6520), S6 (Cell signalling, 2217), p-4EBP1 Thr37/46 
(Cell signalling, 2855), 4EBP1 (Cell signalling, 9644), p-AKT Ser473 and Thr308 (Cell signalling, 
9271 and 9275), AKT (Cell signalling, 4691), p-STAT3 Tyr705 (Cell signalling, 4113 and 
Biolegend, 651021), STAT3 (Cell signalling,9139), p-P65 (Cell signalling, 3031 and 5733), P65 
(Cell signalling, 8242), Vinculin (Sigma, V4505), Iba1 (Wako, 019-19741), CD11b 
(eBiosciences, 17-0112-82) and (Abcam, ab8878), CD45 (Biolenged, 103105), Ki67 (Biolegend, 
652413), Granzymeb (Biolegend, 337221), Perforin (Biolegend, 154406). IFNʏ (Biolegend, 
505826), CD49d (Biolegend, 103618 and 304313), CD44 (Biolegend, 10349), CD62L 
(Biolegend, 104438), CD3 (Biolegend, 152303), CD4 (Biolegend, 100427), CD8 (Biolegend, 
100722 and 100732), PU.1 (Cell signalling, 2258), c-kit (Abcam, ab212518), CD41 (Biolegend, 
303702), CD235a (Lifetechnology, 14-9987-82), P2RY12 (Atlas, HPA014518 and 848006), 
TREM2 (Abcam, ab86491),TMEM119 (Sigma, HPA051870), MHCII (Biolegend, 107607), F480 
(Biolegend, 123130), Sox2 (Santa cruz, sc-17320), NANOG (Biolegend 16H3A38).  
 
Quantification of immunocytochemistry and immunohistochemistry 
For co-expression analysis on tissue, a protocol was developed on Definiens software to 
automatically identify DAPI and the markers of interest. The protocol was composed of the 
following steps: tissue detection, ROI detection and cellular analysis. In tissue detection, the 
program is taught to recognise tissue versus the glass slide. Under ROI detection, the areas of 
interest were defined manually. Under cellular analysis, DAPI or haematoxylin stain was used to 
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identify nucleated cells and the cell marker was used to define area of nucleated cells. The 
software was trained on a subset of tissue regions and then automatically applied to entire 
slides. The number of cells co-expressing the marker of interest and the number of DAB positive 
cells was then calculated. For co-expression analysis on stained cells, the co-locolisation 
threshold tool on ImageJ was used to calculate the % of voxels colocalised between channels. 
 
In silico analysis 
Processing and analysis of RNA-Seq and DNA methylation data 
Total RNA was extracted from sorted cells, cultured cells and FFPE tissue. TAM-MG were 
sorted by gating on single live CD11b+ CD45low cells. Cells were sorted into TRizol (Sigma, 
#93289), and using chloroform (0.2ml per 1ml of TRizol) the aqueous phase was separated by 
centrifugation, from which RNA was extracted using the RNA extraction Microkit (Qiagen, 
74004) following manufacturer’s protocol. Human GBM and GL261 bulk tumour RNA was 
extracted from tumour tissue scrapped off FFPE slides, using the FFPE RNA/DNA Purification 
Plus Kit (NORGEN, 54300) following manufacturer’s protocol. RNA and DNA was extracted 
from cultured cells using the RNA/DNA/Protein Purification Kit (NORGEN, 47700) following 
manufacturer’s protocol. 
Library preparation (SmartSeq2 and NexteraXT) and sequencing (HiSeq4000 75bp pair end 
(Illumina) were carried out at Oxford Genomics Centre. RNA-Seq data were processed using 
two separate pipelines. For hierarchical clustering and principal component analysis, transcript-
level expression was estimated directly using the pseudoalignment package Salmon (Patro et 
al, 2017). The results were then aggregated to obtain gene level expression estimates in units 
of transcripts per million (TPM), which are normalised for library size and transcript length. For 
the purpose of identifying deregulated genes, gene counts were first estimated using the 
gapped alignment software STAR (Dobin et al, 2013). The reference genomes used in both 
pipelines are Ensembl GRCm38 (release 90) for mouse data and Ensembl GRCh38 (release 
90) for human data. DE genes are computed using the R package edgeR (Robinson et al, 
2010), requiring a minimum absolute fold change of 1.5 and a false discovery rate lower than 
0.05. Functional analysis of DE gene lists was carried out on the IPA software. 
DNA methylation data for GIC lines were assayed on the Illumina Human Methylation EPIC or 
450K microarrays. EPIC array data were reduced to include only the same probes as the 450K 
data (these have the same chemical design and are therefore comparable). Raw array data 
were first pre-processed using the ChAMP package in R to remove failed detections and probes 
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with known design flaws (Feber et al, 2014), before normalisation using the SWAN algorithm 
(Maksimovic et al, 2012).  
 
Published transcriptomic dataset used in this study 
Pre-processed gene expression data from the TCGA-GBM RNA-Seq and the Gravendeel-GBM 
Microarray repository were downloaded from the GlioVis data portal (Bowman et al., 2017), 
resulting in 138 samples from the TCGA dataset and 135 samples from the Gravendeel dataset. 
RNA-Seq data published by Bowman et al. in 2016 of TAM-MG, TAM-BMDM, healthy microglia 
and healthy monocytes from the GL261 model were obtained from the GEO database 
(GSE86572). 
 
Computing GBM subgroup based on DNA methylation and transcriptomic profile 
Subgroups of GBM have previously been described based on analysis of methylome data 
(Sturm et al, 2012). Our bulk FFPE and GIC samples were assigned to subgroups on this basis 
using a published random forest classifier (Capper et al., 2018), which requires raw methylation 
array data as an input. Using transcriptomic data from the bulk FFPE and GIC samples as well 
as data from the TCGA cohort, the subgroup were computed according to Wang et al. (Wang et 
al., 2017) using the provided software tool. 
 
Evaluation of immune cell infiltration 
Tumour-infiltrating immune cells were calculated using the CIBERSORT algorithm (Newman et 
al. 2015). CIBERSORT is an analytical tool, with a gene expression signature of 547 marker 
genes, used for quantifying the infiltrated immune cell composition fractions. LM22 is the 
annotated gene signature matrix defining 22 immune cell subtypes, including seven types of T 
cells, naïve B cells, memory B cells, plasma cells, resting and activated NK cells, monocytes, 
M0-M2 macrophages, resting and activated dendritic cells, resting and activated mast cells, 
eosinophils and neutrophils, which were downloaded from the CIBERSORT web portal 
(http://cibersort.stanford.edu/). Immune cell fraction of all the bulk RNAseq samples were 
analysed using the CIBERSORT algorithm. 
 
Calculation of gene signature enrichment scores with ssGSEA 
Gene signatures that discriminate TAM-MG and TAM-BMDM in the context of a mouse tumour 
model were obtained from a study by Bowman et al. (Bowman et al., 2016). These were 
converted into human orthologs using the HomoloGene database provided by NCBI 
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(https://www.ncbi.nlm.nih.gov/homologene, build 68), which resulted in human signatures of 340 
genes for TAM-MG (from 378 mouse genes) and 377 for TAM-BMDM (from 458) (Table S2). A 
human mTOR signature was obtained from the Molecular Signatures Database (mSIGDB, 
(Subramanian et al., 2005) (Table S2). The NF-ĸB (hsa04064) was obtained from the KEGG 
database, the ‘Negative regulation of lymphocyte’ and ‘T cell differentiation’ signature was 
obtained from Luoto et al. (Luoto et al., 2018), and the T cell chemotaxis, antigen presentation, 
STAT3, and IFNγ signatures were obtained from the ssGSEA database (Table S2). 
The function gsva in the homonym package from the R Bioconductor repository was used to 
compute ssGSEA scores, with “method=ssgsea” and default settings. The ssGSEA scores were 
calculated for each of the signatures (Barbie et al., 2009), in the 148 TCGA-GBM samples as 
well as the Rheb1fl/fl and Rheb1Δ/Δ bulk GL261 tumours and TAM-MG RNAseq samples. Scores 
were standardised using a z transform across samples for each signature.  
 
Pearson Correlation analysis 
For the bulk samples, a correlation analysis between CIBERSORT immune cell fraction values 
and ssGSEA enrichment scores was performed separately for each group (fl/fl and Δ/Δ) in R, 
using the CRAN package Hmisc and functions rcorr with default settings, to extract Pearson 
coefficients. To compare correlation coefficients between the two sample groups, the Pearson 
scores where subtracted (Δ/Δ− fl/fl) to obtain a differential correlation score.  
Similarly, for the TAM-MG RNAseq samples, Pearson correlation was calculated across 
signatures ssGSEA enrichment scores. With the TCGA-GBM samples, the Pearson correlation 
was computed between mTOR signature scores and both TAM-MG and TAM-BMDM 
separately. 
 
Statistical analysis and data visualisation 
All statistical analysis was completed using python V2.7 or GraphPad Prism Pro V8. Flow 
cytometry plots and histogram were plotted in Flow Jo V10. All other scatter plots, boxplots were 
plotted with python V2.7, R and relevant Bioconductor packages or GraphPad Prism Pro V8 and 
IPA software (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-
analysis).  
Parametric data are presented as mean± standard error of the mean (SEM). P<0.05 was 
considered statistically significant, with p values <0.05, <0.01, and <0.001 represented with *, **, 
*** respectively. Further information on statistical analysis of specific data sets is indicated in the 
figure legends. 
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Schematics were created using bioRENDER (https://biorender.com/) or IPA software. 
 
Data Availability 
 RNASeq data: Gene Expression of the GL261 TAM-MG and the Bulk GL261 from 
Cx3cr1-Rheb1-/- and Rheb1fl/fl samples (Omnibus GSE147329 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147329) 
 
Other datasets generated in this study are available at the following databases: 
 RNA-Seq data: Gene Expression TCGA-GBM RNA-Seq normalized count reads, 
downloaded from http://gliovis.bioinfo.cnio.es/ 
 RNA-Seq data: Gene Expression TCGA-Gravendeel RNA-Seq normalized count reads, 
downloaded from http://gliovis.bioinfo.cnio.es/ 
 RNA-Seq data: Gene Expression of Bowman et al. dataset 
Omnibus GSE86572 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86572) 
 Methylation Array: 
Omnibus GSE147329 
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Figure Legends 
 
Figure 1 Upregulation of mTOR signalling in TAM-MG but not TAM-BMDM in GBM mouse 
models. 
(A) Representative images of a PDGFB tumour: H&E on the right to identify the tumour, an 
adjacent section stained for Iba1 (red), p-S6 (green) and DAPI (blue) at the centre and the 
region selection for quantification on the left (non-tumour in light blue, tumour edge in orange 
and tumour core in dark blue). (B) Representative images of core, edge and adjacent non-
tumour brain tissue for Iba1, p-S6 and DAPI staining in Pten-/-p53-/- (left) and GL261 (right) 
tumours. Percentage of Iba1+ cells co-expressing p-S6 in the three defined regions. Five high 
grade glioma models were analysed – GL261 (n=3), PDGFB (n=3), Ntv-a;PDGFB+shp53 (n=2), 
Pten-/-p53-/- (n=3), and Pten-/-p53-/-Idh1mut (n=3) (mean ±SEM; Two-Way ANOVA Tukey test). (C) 
Venn diagram identifying significantly deregulated genes in healthy versus GL261 TAM-MG 
and/or TAM-BMDM (GSE68376 dataset). (D) Top-most deregulated canonical pathways in 
GL261 TAM-MG, as identified by the IPA software. Threshold indicates p≤0.05. Z-score 
indicates the orientation of the deregulation. Ratio indicates the number of deregulated genes in 
the pathway. (E) mTOR-related deregulated canonical pathways in GL261 TAM-MG and TAM-
BMDM, as identified by the IPA software. (F) Expression levels of Rps6 and (G) Eif4ebp1 in 
healthy versus GL261 microglia and macrophage (n=3; mean ±SEM). *p≤0.05, **p≤0.01, 
***p≤0.001.  
 
Figure 2 Microglia and BMDM are differently conditioned by mGIC. 
(A) Schematic of the in vitro model whereby microglia and BMDM were pre-treated with Torin, 
LY294002 as indicated and stimulated with mGL261, mGICPten-/-;p53-/--CM or mNSC-CM. 
Signalling was analysed in microglia by immunoblotting of whole cell lysates collected at 4hr (B, 
D and F) and 0.5hr (H) and normalised against non-phosphorylated protein and vinculin 
analysed on the same blot. Flow cytometry analysis was carried out in microglia for (C) p-S6 
S240/244; (E) p-4EBP1 T37/46; (G) p-AKT S473; and (I) p-AKT T308. Each treatment (mNSC-
CM, Pten-/-p53-/- mGIC-CM, Pten-/-p53-/- mGIC-CM+Torin, mGIC-CM+LY) was normalised to 
unconditioned control (n=3; mean ±SEM, Two-Way ANOVA Tukey test). *p≤0.05, **p≤0.01, 
***p≤0.001 comparing mGICPten-/-;p53-/--CM  versus mGICPten-/-;p53-/--CM +inhibitor. 
 
Figure 3 Genetic inhibition of mTORC1 signalling in Cx3cr1+ TAM impacts tumour growth 
and survival. 
   
 
Page 34 of 44 
 
(A) Schematic of the generation and analysis of the Cx3cr1-Cre;Rheb1-loxp GL261 model. (B) 
Survival analysis for Cx3cr1-Rheb1Δ/Δ (n=5) and Rheb1fl/fl (n=7) mice. Chi square test. (C) 
Representative images and quantification of the tumour volume with MRI of Rheb1fl/fl (n=8) 
compared to Cx3cr1-Rheb1Δ/Δ (n=8) mice. Unpaired parametric t test. (D) H&E staining showing 
representative histological features (overview and high magnification of microvascular 
proliferation) of Rheb1fl/fl and Cx3cr1-Rheb1Δ/Δ GL261 tumours. (E) Percentage of GFP+ CD45- 
GL261 tumour cells in Cx3cr1-Rheb1Δ/Δ (n=6) and Rheb1fl/fl (n=6) tumours, with representative 
FACS plot (mean ±SEM; Unpaired parametric t test). **p≤0.01, and ***p≤0.001  
 
Figure 4 Genetic inhibition of mTORC1 signalling in TAM affects the immune profile of 
GL261 tumours 
(A) Significantly deregulated canonical pathways in Cx3cr1-Rheb1Δ/Δ versus Rheb1fl/fl GL261 
tumours, as identified by the IPA software from differentially regulated genes and divided in 
three categories: Adaptive immunity, Cytokine signalling, and Innate immunity. Size of bubbles 
is indicative of ratio of differentially regulated genes. The x-axis represents –log10(p-value) with 
a threshold of p≤0.05 applied. (B) Levels of TAM-MG (P2RY12+ CD49d-) and TAM-BMDM 
(P2RY12- CD49d+) gated from CD45+ population in GL261 tumours from Rheb1fl/fl (n=4) and 
Cx3cr1-Rheb1Δ/Δ (n=5) mice by flow cytometry (representative flow cytometry plots on top and 
quantification at the bottom). Two-Way ANOVA Tukey test. (C) Percentage of CD8 CTL (top) 
and CD4 Th (CD4) cells in GL261 tumours from Rheb1fl/fl (n=4) and Cx3cr1-Rheb1Δ/Δ (n=5) mice 
assessed by flow cytometry (representative flow cytometry plots, left and quantification, right). 
Unpaired t test. (D) Tumour tissues from Rheb1fl/fl (n=4) and Cx3cr1-Rheb1Δ/Δ (n=4) were 
stained for CD8, CD4 and FoxP3. DAB staining was quantified as % of positive cells using 
Definiens software. Representative images of the stained tissues are shown (Scale bar 100µm) 
(mean ±SEM; unpaired parametric t test).  *p≤0.05, and **p≤0.01  
 
Figure 5 Genetic inhibition of mTORC1 signalling in TAM affects the immune reactivity of 
T cells. 
(A) Schematic of the analysis of bulk GL261 RNAseq data from Cx3cr1-Rheb1Δ/Δ (n=3) and 
Rheb1fl/fl (n=3) mice. ssGSEA enrichment scores for signalling pathway signatures and 
CIBERSORT cell fractions were calculated for each sample. Pearson correlation score was then 
calculated comparing signalling pathway enrichment scores and CIBERSORT cell fractions. 
Finally, a differential correlation analysis was run between the Cx3cr1-Rheb1Δ/Δ (n=3) and 
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Rheb1fl/fl (n=3) samples. (B) Heatmap of the differential correlation analysis between 
CIBERSORT cell fractions and signatures enrichment scores (ssGSEA) for lymphocytes in the 
Cx3cr1-Rheb1Δ/Δ (n=3) vs Rheb1fl/fl (n=3) GL261 tumours. (C) CD4 Th cells and (D) CD8 CTL 
cells expression of Ki67, perforin, granzyme b, and IFN, in Cx3cr1-Rheb1fl/fl (n=5) and Rheb1Δ/Δ 
(n=5) GL261 tumours. Representative FACS plots show control samples (tumour-derived cells 
stimulated in culture in the absence of protein inhibitor cocktail – in orange) compared to 
stimulated cells derived from Rheb1fl/fl (fl/fl, red) and Cx3cr1-Rheb1Δ/Δ (Δ/Δ, blue) GL261 
tumours (cells stimulated in culture with protein inhibitor cocktail) (mean ±SEM; Two-Way 
ANOVA Tukey test). (E) Expression of CD44 and (F) CD62L by CD4 Th and CD8 CTL in 
Cx3cr1-Rheb1fl/fl (n=5; fl/fl, red) and Rheb1Δ/Δ (n=5; Δ/Δ, blue) GL261 tumours with 
representative FACS plots show control samples (mean ±SEM; Two-Way ANOVA Tukey test). 
*p≤0.05, **p≤0.01 
 
Figure 6 mTOR inhibition in TAM-MG induces a pro-inflammatory tumour 
microenvironment via the regulation of STAT3 and NF-ĸB transcription factors 
(A) Significantly deregulated canonical pathways in GL261 Rheb1fl/fl versus Rheb1Δ/Δ TAM-MG, 
as identified by the IPA software from differentially regulated genes. The x-axis represents –
log10(p-value) with a threshold of p≤0.05 applied. On the right, number of up and down 
regulated genes in each identified pathway is indicated in blue and red respectively. (B) 
Frequency of occurrence of differentially regulated genes across significantly deregulated 
canonical pathways compared to the Log fold change (Log(FC)). (C) Upstream regulators as 
identified by the IPA software from differentially regulated genes. (D) Heatmap of Pearson 
correlation analysis between ssGSEA signatures enrichment scores in the Rheb1fl/fl versus 
Cx3cr1-Rheb1Δ/Δ GL261 tumours. (E) Microglia were pre-treated with Torin, or medium as 
indicated and then stimulated with mNSC-CM, mGICPten-/-;p53-/--CM, or GL261-CM. p-NF-ĸB (p-
P65) and p-STAT3 were analysed by immunoblotting of whole cell lysates collected at 4hr. (F) 
Immunofluorescence images of NF-ĸB (P65) in conditioned microglia and BMDM (left). 
Quantification of nuclear translocation of NF-κB from staining. Units represent the % of voxels in 
the NF-κB channel colocalised with DAPI (n=3, mean ±SEM, One-Way ANOVA Tukey test – 
right). (G) Production of Il-12p40, Tnf, Il6, and Il10 by conditioned microglia was determined by 
qPCR. Each treatment was normalised to housekeeping gene and the unconditioned control. 
(n=3; mean ±SEM, Two-Way ANOVA Tukey test). (H) MFI levels of pSTAT3 and (I) p-NF-B (p-
P65) in TAM-MG (CD45+ P2RY12+ CD49d-) and TAM-BMDM (CD45+ P2RY12- CD49d+) from 
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Rheb1fl/fl (fl/fl, blue, n=4) and Cx3cr1-Rheb1Δ/Δ (Δ/Δ, red, n=5) GL261 tumours. Representative 
FACS plots are displayed for each cell type. *p≤0.05, **p≤0.01, ***p≤0.001. 
 
Figure 7 mTOR signalling in TAM-MG promotes immune evasion mechanisms in human 
glioblastoma. 
(A) Correlation between ssGSEA enrichment scores for the mTOR signature versus TAM-MG or 
TAM-BMDM signatures in TCGA GBM transcriptomic data. Comparison carried out on all IDH-
wild-type samples, and in a subgroup specific manner according to Wang’s classifier. Size of 
circle is indicative of Rsquare value and bold outline represents a p-value ≤0.05. (B) Separation 
of IDH-wildtype GBM samples between those displaying high mTOR and microglia enrichment 
(+ve correlation, group 1 in orange) and those without this signature (group 2 in green). (C) 
CIBERSORT cell fractions calculated from the TPM of TCGA IDH-wild type GBM samples from 
group 1 compared to those from group 2 (mean ±SEM). (D) Heatmap of Pearson correlation 
analysis comparing ssGSEA enrichment scores of TAM-MG and TAM-BMDM signatures versus 
signalling pathway signatures, calculated from the TPM of IDH-wild type GBM samples with the 
signature from group 1. (E) Schematic of the experimental setup to derive patient-matched 
EPSC and GIC lines. (F) Staining by flow cytometry of EPSC, YS-EBs and matched-iMGL with 
indicated markers. Mature iMGL were immunostained for (G) PU1 and CD11b and (H) Iba1 and 
TREM2. Scale bar 20µm. (I) P-S6, (J) p-STAT3, and (K) p-NF-ĸB (p-P65) were analysed by flow 
cytometry in iMGL, pre-treated with Torin, as indicated and then stimulated with matched patient 
EPSC- or hGIC-CM. (n=3; mean ±SEM, Two-Way ANOVA Tukey test). *p≤0.05, **p≤0.01, 
***p≤0.001. 
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Expanded View Figure Legends 
 
Figure EV1 
(A) Quantification of immunoblotting analysis from conditioned microglia whole cell lysates at 
4hr incubation for p-S6, p-4EBP1, p-AKT S473, and at 0.5hr incubation for p-AKT T308. Data 
normalised to non-phosphorylated protein and to vinculin. (B) Representative flow cytometry 
plots of microglia under different culture condition at 4hr incubation for p-S6, p-4EBP1, p-AKT 
S473, and at 0.5hr incubation for p-AKT T308. (C) Signalling was analysed in conditioned 
BMDM by immunoblotting of whole cell lysate collected at 4hr for p-S6, p-4EBP1, p-AKT S473, 
and (D) at 0.5hr incubation for p-AKT T308, (E) which was quantified by normalisation with non-
phosphorylated protein and vinculin. (F) Flow cytometry analysis was carried out in BMDM for p-
S6, p-4EBP1, p-AKT S473; p-AKT T308. Each treatment was normalised to unconditioned 
control (n=3; mean ±SEM, Two-Way ANOVA Tukey test). 
 
Figure EV2 
(A) Representative flow cytometry plot for the expression of CD45 and CD11b in GL261 tumour, 
with CD45high CD11b+ TAM-BMDM (top gate) and CD45low CD11b+ TAM-MG (lower gate). (B) 
Representative flow cytometry plot of YFP (left) and p-S6 (right) levels in TAM-BMDM (top) and 
TAM-MG (bottom) in Cx3cr1-Rheb1Δ/Δ (blue) versus Rheb1fl/fl (red) GL261 tumours. (C) 
Percentage of TAM-MG and TAM-BMDM expressing YFP in Cx3cr1-Rheb1Δ/Δ (n=6) and 
Rheb1fl/fl (n=6) mice. MFI levels of p-S6 in P2RY12+ CD49d- TAM-MG and P2RY12- CD49d+ 
TAM-BMDM with representative FACS plots from of Rheb1fl/fl (n=6) compared to Cx3cr1-
Rheb1Δ/Δ (n=6) GL261 tumours (Two-Way ANOVA Tukey test). (D) Staining for Iba1, p-S6, and 
DAPI in Rheb1fl/fl (n=3) and Cx3cr1-Rheb1Δ/Δ (n=2) tumour tissue (left) and percentage of Iba1+ 
cells co-expressing p-S6 in the three defined regions (right) (E) Isotype control stain 
demonstrating quenching of fluorescence from reporter gene (scale bar 50m) (mean ±SEM; 
Two-Way ANOVA Tukey test). *p≤0.05, **p≤0.01, ***p≤0.001. 
 
Figure EV3 
(A) Principal component analysis of bulk (triangle) and TAM-MG (circle) RNAseq samples from 
Rheb1fl/fl (red) and Cx3cr1-Rheb1Δ/Δ (blue) Gl261 tumours. (B) Volcano plot of differentially 
expressed genes between Rheb1fl/fl (n=3) and Cx3cr1-Rheb1Δ/Δ (n=3) GL261 tumours. Red and 
blue points mark genes with significantly increased or decreased expression respectively 
(FDR≤0.05). The x-axis shows expression log fold changes (FC) and the y-axis shows the –log 
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of the false discovery rate (FDR). (C) Expression levels (TPM) of Csf1r, Csf1, Aif1 (Iba1), Itgam 
(Cd11b), Cd274 (PD-L1) in Cx3cr1-Rheb1Δ/Δ (n=3) versus Rheb1fl/fl (n=3) (mean ±SEM). * 
FDR≤0.05, ***FDR≤0.001. (D) CIBERSORT cell fractions calculated from the TPM of Cx3cr1-
Rheb1Δ/Δ (n=3) versus Rheb1fl/fl (n=3; mean ±SEM). *p≤0.05. 
 
Figure EV4 
(A) ssGSEA enrichment scores from TAM-MG and TAM-BMDM signature in Rheb1fl/fl (n=2) and 
Cx3cr1-Rheb1Δ/Δ (n=3) RNAseq from TAM-MG of GL261 tumours (B) Volcano plot of differential 
expression analysis of genes between Rheb1fl/fl (n=2) and Cx3cr1-Rheb1Δ/Δ (n=3) TAM-MG. 
Red and blue points mark genes with significantly increased or decreased expression, 
respectively (pvalue≤0.02). The x-axis shows expression log fold changes (FC) and the y-axis 
shows the –log of the false discovery rate (p value). (C) Expression levels of Isg15 and Usp18 in 
Cx3cr1-Rheb1Δ/Δ (n=3) versus Rheb1fl/fl TAM-MG (n=2). (D) Schematic representation of the 
NF-ĸB pathway with genes deregulated in Cx3cr1-Rheb1Δ/Δ versus Rheb1fl/fl TAM-MG. Pink 
circles indicate deregulated expression of the protein, which when coloured green is 
downregulated and in pink upregulated. (E) Deregulated canonical pathways in GL261 TAM-MG 
and TAM-BMDM, as identified by the IPA software between Cx3cr1-Rheb1Δ/Δ and Rheb1fl/fl 
TAM-MG. (F) Quantification of immunoblotting analysis from conditioned microglia whole cell 
lysates at 4hr incubation for p-NF-κB (p-P65) and p-STAT3, normalised to non-phosphorylated 
protein and vinculin. (G) Signalling was analysed in conditioned BMDM by immunoblotting of 
whole cell lysates collected at 4hr for p-NF-κB (p-P65) and p-STAT3, which was normalised to 
non-phosphorylated protein and vinculin. (H) Quantification of nuclear translocation of NF-κB 
(P65) from immunofluorescence staining. Unit represent the % of voxels in the NF-κB channel 
colocalised with DAPI (One-Way ANOVA Tukey tests). (I) Flow cytometry analysis of p-STAT3 
in conditioned microglia and BMDM (Two-Way ANOVA Tukey tests). *p≤0.05, **p≤0.01, 
***p≤0.001 (mean ±SEM). 
 
Figure EV5 
(A) Correlation between ssGSEA enrichment scores for the mTOR signature versus TAM-MG or 
TAM-BMDM signatures in Gravendeel GBM transcriptomic data. Comparison carried out on all 
IDH-wild-type samples, and in a subgroup specific manner according to Wang’s classifier. Size 
of circle is indicative of Rsquare value and bold outline represents a p-value ≤0.05. (B) 
Representative images of differentiation protocol of EPSC into EBS, YS-EBs and iMGL. (C) 
Representative flow cytometry plots for changes in expression of surface markers during 
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differentiation of EPSC to iMGL. Histogram of expression of SOX2 (stem cell marker), PU.1 
(early yolk sac marker), P2RY12 (microglia specific marker) and CD49d (macrophage specific 
marker) by EPSC, YS-EBs, and iMGL are shown. (D) Representative flow cytometry plots of 
expression of p-S6, p-STAT3, and p-NF-κB (p-P65) in iMGL following 4hr of incubation with 
different culture conditions. 
 
Expanded View Datasets 
Dataset EV1: Pathways identified as significantly enriched by IPA software based on 
differentially regulated genes between healthy microglia and TAM-MG. 
Dataset EV2: Pathways identified as significantly enriched by IPA software based on 
differentially regulated genes between Rheb1Δ/Δ and Rheb1fl/fl bulk GL261 and in TAM-MG. 
 
Expanded View Tables: 
Table EV1: Gene signatures used to calculate ssGSEA enrichment scores 
Table EV2: Differential correlation analysis calculated between CIBERSORT cell fractions and 
ssGSEA enrichment scores for each signature. 
Table EV3: ssGSEA enrichment scores calculated for each signature per TCGA GBM bulk 
transcriptomic data 
Table EV4: Clinical and molecular data relating to the primary GBM lines presented in this 
study. 
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